Turning Natural Variation into Product Innovation and Sustainable Growth
Fibriant leverages its expertise in fibrinogen technology to develop innovative healthcare solutions based on specific, naturally occurring, variants of human fibrinogen. Human fibrinogen plays a pivotal role in blood clotting, tissue repair and host defense against pathogens. The company has developed a pilot manufacturing process for recombinant production of different fibrinogen variants and has demonstrated pre-clinical proof of concept for specific fibrinogen variants as topical hemostat and as anti-virulence factor in staphylococcus aureus infections. Fibriant executes a hybrid business model focused on sustainable growth and is led by a team with extensive scientific, product development and business experience.
Speaker: Jaap Koopman, Founder and CEO
Jaap Koopman has over 35 years of experience in bio-medical R & D, of which 20 years in the biotech industry. In 2004 he founded ProFibrix BV and led this company as CEO through multiple venture finance rounds. As CSO he supported the development of a dry powder fibrin sealant product to approval in US and EU and was part of the management team that led the acquisition of ProFibrix BV by The Medicine Company in August 2013. In 2015 Jaap founded Fibriant BV, that is focussed on development of a recombinant fibrinogen technology platform, and currently is the CEO of this company.
The audience picked Healthy Mind, Iova and PharmaCytics as their top 3 pitchers and of these the jury chose PharmaCytics as the winner of the Axon Innovation for Health Award.